

Enstilar - (0.005%/0.064%; Aerosol, Foam)

Generic Name	Calcipotriene and Betamethasone Dipropionate	Innovator	Leo Pharma
Dosage	0.005%/0.064%; Aerosol, Foam	Branded US Sales	Less Than \$1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Enstilar Foam is indicated for the topical treatment of plaque psoriasis in patients 18 years of age and older		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.